Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Long acting HIV drugs to be developed

HIV drugs which only need to be taken once a month are to be developed at the University of Liverpool in a bid to overcome the problem of ‘pill fatigue’.

Published
15 September 2014
From
University of Liverpool press release
Change to recommended regimen for post-exposure prophylaxis (PEP)

The Expert Advisory Group on AIDS (EAGA) has recommended a change in the recommended regimen for post-exposure prophylaxis from tenofovir/emtricitabine with Kaletra to tenofovir/emtricitabine with raltegravir.

Published
11 September 2014
From
Expert Advisory Group on AIDS (EAGA)
A "Bad Year" for HIV Cure Research? Experts Mix Realism and Hope

At ICAAC 2014, a major gathering of infectious disease experts, we heard speeches and spoke with leading HIV researchers about their evolving feelings regarding our fraught pathway toward a cure and the efforts currently underway to get us there.

Published
11 September 2014
From
The Body Pro
New medicines in development give hope to patients with HIV/AIDS

America’s biopharmaceutical research companies are currently developing 44 medicines and vaccines for HIV/AIDS treatment and prevention, according to the latest Medicines in Development report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Published
11 September 2014
From
Pharmaceutical Research and Manufacturers of America
SIV Reservoir Fills Before Viremia in Rectally Infected Monkeys

In macaques rectally infected with simian immunodeficiency virus (SIV), the latent viral reservoir starts to fill with proviral DNA before viral RNA can be detected in peripheral blood. Findings from this study could help explain why HIV rebounded in the Mississippi child after being undetected for over 2 years.

Published
11 September 2014
From
International AIDS Society
Pregnant women need more support on looking after their own health after childbirth – could help retention in Option B+ programmes

Many women living with HIV believe that HIV care for the mother’s own health is unimportant once the baby is born, especially if the infant tests HIV

Published
10 September 2014
By
Roger Pebody
New HIV Drug, BMS-986001, Safe and Effective in Treatment-Naive Patients

BMS-986001, a novel thymidine analog NRTI (nucleoside reverse transcriptase inhibitor) being developed by Oncolys BioPharma, when combined with efavirenz (Sustiva, Stocrin) and lamivudine (3TC, Epivir), was found to have comparable efficacy to tenofovir (Viread) in treatment-naive patients living with HIV, according to phase-2b study results presented by Samir K. Gupta, M.D., M.S., at ICAAC 2014 in Washington, D.C.

Published
10 September 2014
From
The Body
Drug-level study shows feasibility of long-acting integrase inhibitor cabotegravir

A pharmacokinetic (PK) analysis presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC, confirmed that the long-acting HIV integrase inhibitor cabotegravir (formerly GSK1265744) reaches adequate target levels in the blood, setting the stage for efficacy trials for HIV treatment and pre-exposure prophylaxis (PrEP).

Published
10 September 2014
From
HIVand hepatitis.com
After two years on antiretroviral therapy, survival in South African patients meets rates from North America

Provided that therapy is started promptly, South Africans with HIV have chances of remaining alive beyond two years on antiretroviral therapy that are comparable to those of North American patients, according to new research.

Published
10 September 2014
From
Science Daily
Uganda: Aids Patients Reject Bitter ARVs

The Uganda Coalition for Access to Essential Medicine (UCAEM) has asked government to withdraw and cease use of non-film coated tenofovir and lamivudine, dubbing the drug combination as notoriously bitter. "People living with HIV will more likely stop taking treatment than use this medicine," said Margaret Happy, the advocacy officer of the International Community of Women in East Africa (ICWEA).

Published
10 September 2014
From
Allafrica.com

Filter by country